Necrotizing Myopathy (NM)Symptoms, Doctors, Treatments, Advances & More
Necrotizing Myopathy (NM) Overview
Learn About Necrotizing Myopathy (NM)
Johns Hopkins Bayview Medical Center
Andrew Mammen is a Neuromusculoskeletal Medicine specialist and a Neurologist practicing medicine in Baltimore, Maryland. Dr. Mammen is rated as an Elite provider by MediFind in the treatment of Necrotizing Myopathy (NM). He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Myositis, Polymyositis, Dermatomyositis, and Necrotizing Myopathy (NM). Dr. Mammen is board certified in American Board Of Psychiatry And Neurology. Dr. Mammen is currently accepting new patients.
MN - Neuro
Margherita Milone is a Neurologist practicing medicine in Rochester, Minnesota. Dr. Milone is rated as an Elite provider by MediFind in the treatment of Necrotizing Myopathy (NM). She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Progressive External Ophthalmoplegia, Necrotizing Myopathy (NM), Nemaline Myopathy, and Congenital Fiber-Type Disproportion. Dr. Milone is board certified in MN State Medical License 2003-2023.
Olivier Benveniste practices practicing medicine in Paris, France. Mr. Benveniste is rated as an Elite expert by MediFind in the treatment of Necrotizing Myopathy (NM). He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Myositis, Necrotizing Myopathy (NM), Antisynthetase Syndrome, Inclusion Body Myositis, and Kidney Transplant.
Summary: This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy. The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in treating early, active autoantibody positive immune-mediated necrotizing myopathy using the validated ...
Summary: This is a randomized, placebo-controlled, double blinded phase 2 exploratory clinical trial of intravenously administered pooled human immunoglobulin (IVIG) in anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune mediated necrotizing myopathy (IMNM). Planned enrollment is 12 individuals with active anti-HMGCR IMNM meeting inclusion and exclusion criteria. Assuming 20% drop-out, the investi...
